Skip to content

A multicenter, prospective, randomized, non-inferior controlled trial for comparing the efficacy and safety of short-term VrD and long-term VRD regimens in the treatment of initial diagnosis of multiple myeloma

A multicenter, prospective, randomized, non-inferior controlled trial for comparing the efficacy and safety of short-term VrD and long-term VRD regimens in the treatment of initial diagnosis of multiple myeloma

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900027789
Enrollment
Unknown
Registered
2019-11-28
Start date
2019-12-01
Completion date
Unknown
Last updated
2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

2:long term VRD
2:short term VrD

Sponsors

the First Affiliated Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of newly diagnosed MM patients by IMW diagnostic criteria; 2. Aged 50-80 years old; 3. ECOG score 0-2; Liver and kidney function: blood bilirubin =30ml/min, calculation formula: Male: creatinine clearance = [(140-age)x body weight (kg)]/[0.818 x serum creatinine concentration (umol/L)], or creatinine clearance = [(140 - age) x body weight (kg)] /[72 x serum creatinine concentration (mg / dl)]; women calculated according to the above formula x 0.85; 4. normal heart function: EF>50%; 5. Expected survival >=3 months; 6. Obtain informed consent signed by the patient or family member.

Exclusion criteria

Exclusion criteria: 1. There are other history of malignant tumors in the past 5 years; 2. HIV-positive, active tuberculosis, clinically active patients with hepatitis A, B, and C; 3. Other serious diseases that may limit the patient's participation in this trial (eg, advanced infection, uncontrolled diabetes, severe cardiac insufficiency or angina); 4. Systemic conditions are not suitable for chemotherapy; 5. pregnant or lactating women; 6. Combine other serious organic diseases and mental disorders; 7. Can't understand or follow the research plan.

Design outcomes

Primary

MeasureTime frame
Complete remission;ORR;

Secondary

MeasureTime frame
PFS;MRD;safety;

Countries

China

Contacts

Public ContactHaitao Meng

the First Affiliated Hospital of Zhejiang University School of Medicine

menghait2004@163.com+86 13989823604

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026